Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI9090 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MEDI9090 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MEDI9090 | BIOLOGICAL | MEDI9090 will be administered by IV infusion |
| Durvalumab | BIOLOGICAL | Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090. |
Inclusion Criteria: * Male and female subjects * 18 years and older * Must have histologic documentation of advanced solid tumors * Must have received and have progressed, are refractory or, intolerant to standard therapy and must not have a curative therapy option Exclusion Criteria: * Concurren...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MEDI9090 is an investigational monoclonal antibody being developed for the treatment of advanced solid tumors. It is currently in clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with advanced solid tumors to evaluate its safety and pharmacokinetics.
MEDI9090 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. AstraZeneca is conducting clinical trials to evaluate the safety and pharmacokinetics of MEDI9090 in patients with advanced solid tumors.
MEDI9090 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 1 trial is designed to evaluate the safety and pharmacokinetics of MEDI9090 in patients with advanced solid tumors.
MEDI9090 has one completed clinical trial, registered under the identifier NCT02900157. The trial was a Phase 1 study titled 'Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors.' It enrolled 42 participants in the United States and Japan, with a minimum age of 18 years.
MEDI9090 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial focused on evaluating safety and pharmacokinetics, and the drug has not yet progressed to later-stage trials or received regulatory approval.